Advertisement

Serum NMDA Receptor Antibodies Do Not Predict Treatment Response in a Sample of People With First-Episode Psychosis

      SEE CORRESPONDING ARTICLE ON PAGE 9
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rickards H.
        • Jacob S.
        • Lennox B.
        • Nicholson T.
        Autoimmune encephalitis: A potentially treatable cause of mental disorder.
        Adv Psychiatr Treat. 2014; 20: 92-100
        • Pollak T.A.
        • Lennox B.R.
        • Müller S.
        • Benros M.E.
        • Prüss H.
        • Tebartz van Elst L.
        • et al.
        Autoimmune psychosis: An international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin.
        Lancet Psychiatry. 2020; 7: 93-108
        • Scott J.G.
        • Gillis D.
        • Ryan A.E.
        • Hargovan H.
        • Gundarpi N.
        • McKeon G.
        • et al.
        The prevalence and treatment outcomes of antineuronal antibody-positive patients admitted with first episode of psychosis.
        BJPsych Open. 2018; 4: 69-74
        • Moran N.
        Encephalitis and psychosis.
        Br J Psychiatry. 2012; 200: 428
        • The American Psychiatric Association
        The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia.
        American Psychiatric Association, Washington, DC2021
        • Barnes T.R.
        • Drake R.
        • Paton C.
        • Cooper S.J.
        • Deakin B.
        • Ferrier I.N.
        • et al.
        Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology.
        J Psychopharmacol. 2020; 34: 3-78
        • Dahm L.
        • Ott C.
        • Steiner J.
        • Stepniak B.
        • Teegen B.
        • Saschenbrecker S.
        • et al.
        Seroprevalence of autoantibodies against brain antigens in health and disease.
        Ann Neurol. 2014; 76: 82-94
        • Pollak T.A.
        • Vincent A.
        • Iyegbe C.
        • Coutinho E.
        • Jacobson L.
        • Rujescu D.
        • et al.
        Relationship between serum NMDA receptor antibodies and response to antipsychotic treatment in first-episode psychosis.
        Biol Psychiatry. 2021; 90: 9-15
        • Kahn R.S.
        • Winter van Rossum I.
        • Leucht S.
        • McGuire P.
        • Lewis S.W.
        • Leboyer M.
        • et al.
        Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): A three-phase switching study.
        Lancet Psychiatry. 2018; 5: 797-807
        • Warren N.
        • O’Gorman C.
        • McKeon G.
        • Swayne A.
        • Blum S.
        • Siskind D.
        Psychiatric management of anti-NMDAR encephalitis: A cohort analysis.
        Psychol Med. 2021; 51: 435-440

      Linked Article